DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Lau-7b

Phase Two

Phase Two

Therapeutic Approach

Anti-Inflammatory

LAU-7b is an oral compound. It is a form of the retinoid fenretinide. Retinoids are a group of compounds related to vitamin A. Fenretinide may help reduce the inflammatory response in the lungs of people with CF.

Status

A phase 2 study will begin in 2017 to test the safety and effectiveness of LAU-7b in people with CF.

Sponsor

This program is sponsored by Laurent Pharmaceuticals. It is being conducted within the Cystic Fibrosis Foundation's Therapeutics Development Network.

Contact us about Lau-7b >